KS-KCAS
12.9.2022 12:04:33 CEST | Business Wire | Press release
KCAS Bioanalytical and Biomarker Services (KCAS), a leading bioanalytical contract research organization (CRO), backed by Vitruvian Partners, closed the purchase of Active Biomarkers, located in Lyon, France. Active Biomarkers is a renowned assay development and specialty bioanalytical laboratory with expertise in oncology, infectious disease, inflammation and neurodegenerative disorders. Financial terms were not disclosed. Formerly owned by its management team and Turenne Santé fund, Active Biomarkers operates in a new, state-of-the-art facility in Lyon, France with significant expansion opportunities. This transaction adds valuable bioassay and cellular analysis expertise as well as European capacity to support customers globally as KCAS continues to advance its mission of providing high quality bioassay services to the biotech and pharmaceutical industries. The acquisition of Active Biomarkers is the second in 2022 by KCAS. FlowMetric, a leading flow cytometry and cellular analysis CRO, joined KCAS in early 2022. The Lyon site adds to KCAS and FlowMetric’s existing facilities in Kansas, Philadelphia and Milan, Italy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005063/en/
Active Biomarkers building in Lyon, France (Photo: Business Wire)
John Bucksath, CEO of KCAS, stated “We are delighted to partner with the Active Biomarkers team, accelerating our combined offering to support the customers we serve globally. The combined expertise and capacity of KCAS, FlowMetric, and Active Biomarkers is unique. The high-quality, science-first and client-centric culture we all share is key to our commitment to become the CRO partner of choice for the global pharma and biopharma industries. KCAS has embarked on significant investments, including a purpose-built 70,000 sq. ft. facility in Kansas City and a 26,000 sq. ft. facility in Pennsylvania, and accelerating our international footprint through acquisitions. We continue to attract the industry’s top scientific talent and focus on outstanding science and customer service. With our investors, Vitruvian Partners, we are optimally positioned to invest in our people and deliver world-class services for our growing client base. The acquisition of Active Biomarkers gives our combined clients access to further scientific expertise and support in both markets regionally and internationally.”
Marc Essodaigui, CEO of Active Biomarkers, comments, “Our entire team is thrilled about the new partnership with KCAS and the combined organizations’ outlook. This combination will allow us to provide even more comprehensive, best-in-class services for the biopharma and life sciences sector. The KCAS’ alliance, backed by a leading world-class growth investor, will provide us with the support and growth to expand our technological expertise, capacity, and geographical footprint.”
Sophie Bower-Straziota, Partner at Vitruvian Partners, comments, “Active Biomarkers has built a strong reputation in Europe founded in scientific excellence. The company fits with our investment strategy of backing best-in-class operations offering services to a market with strong tailwinds and internationalization opportunities. The acquisition of Active Biomarkers by KCAS builds on the excellent foundation KCAS has built in the US and supports the increasingly international needs of the company’s growing pharmaceutical and biotech clients. As the drug development market continues to evolve, we will continue to support investment in scientific capabilities, broadening geographical reach, providing the resources to scale the business, and making strategic acquisitions.”
About KCAS - KCAS is a rapidly growing company that provides comprehensive GLP compliant development services from early discovery support through product registration and beyond. One of only a select few CROs offering both large and small molecule development with extensive capabilities and expertise, KCAS provides a truly differentiated approach to its clients who are looking for both scientific expertise and excellent customer service. KCAS is headquartered in Olathe, Kansas – the Kansas City metro area and employs more than 300 employees. Website: KCASBio.com.
About Active Biomarkers – Founded in 2011, Active Biomarkers is an integrated bioanalytical laboratory offering a wide range of services, including PK, immunogenicity, soluble and cellular biomarker analyses for clinical studies. Operating in state-of-the-art BSL2 facilities, GCLP accredited and ISO 9001:2015 certified, the company has a unique track-record in the development, validation, and implementation of analytical methods. Its expert team has supported hundreds of studies in multiple therapeutic areas: oncology, infectious diseases, inflammatory pathologies, and neurodegenerative diseases. Beyond its state-of the-art flow cytometry and ELISpot capabilities, Active Biomarkers offers the broadest panel of immunoassay technologies in Europe, ranging from standard ELISA to multiplexed methods such as Luminex, SP-X or ELLA systems, or ultra-sensitive technologies such as MSD, Gyrolab or Simoa HD-X platforms. Website: active-biomarkers.com
About Vitruvian - Vitruvian is a leading international growth investor headquartered in London with additional offices in Stockholm, Madrid, Munich, Luxembourg, San Francisco, Singapore and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries. Vitruvian has backed over 90 companies and has assets under management of approximately €10 billion. Website: vitruvianpartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005063/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bentley Systems Announces 2026 Year in Infrastructure Event and YII Awards Honoring the World’s Most Innovative Use of Infrastructure Engineering Software18.3.2026 13:00:00 CET | Press release
Awards build on a two-decade legacy of recognized innovation, setting the benchmark for excellence across the world’s most critical infrastructure assetsCall for nominations now open; submissions will be accepted through May 3, 2026 Bentley Systems, Incorporated (NASDAQ: BSY), the infrastructure engineering software company, today announced the opening of submissions for the Year in Infrastructure event and YII Awards program, which recognizes digital innovation in how infrastructure is designed, built, and operated using Bentley software. Submissions will be accepted through May 3, at 11:59 p.m. EDT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318559906/en/ Bentley Systems announced the opening of submissions for the Year in Infrastructure event and YII Awards program, which recognizes digital innovation in how infrastructure is designed, built, and operated using Bentley software. Submissions will be accepted through
Veracode Expands Industry-Leading Fix with AI-Powered SCA Remediation to Combat Software Supply Chain Risk18.3.2026 13:00:00 CET | Press release
New Capability Automates Open-Source Vulnerability Remediation as Software Supply Chain Attacks Surge RSA Conference (booth #435)--Veracode, the global leader in application risk management, today announced Veracode Fix for Software Composition Analysis (SCA), an AI-powered solution to address software supply chain risk. The enhanced automated remediation engine—the next evolution of Veracode’s industry-leading Fix solution—enables organizations to detect and remediate open-source vulnerabilities easily, before code reaches production. Designed to integrate seamlessly into existing developer workflows, it delivers third-party updates and first-party code refactoring without breaking builds or disrupting development. In 2025, software supply chain breaches accounted for 30 percent of external attacks. Meanwhile Veracode’s 2026 State of Software Security (SoSS) Report revealed 82 percent of organizations struggle with escalating security debt, largely due to open-source dependencies. Ver
Armis Appoints Simon Mouyal as Chief Marketing Officer18.3.2026 13:00:00 CET | Press release
Strategic marketing executive to accelerate adoption of Armis Centrix™ in the agentic AI era and extend the company’s category leadership in cyber exposure management and CPS security Armis, the cyber exposure management & security company, today announced the appointment of Simon Mouyal as Chief Marketing Officer. In this role, Mouyal will oversee Armis’ global marketing strategy and execution to accelerate category leadership and demand for Armis Centrix™, the Armis Cyber Exposure Management Platform. During the next phase of Armis’ expansion, he will scale the global marketing organization and help further drive the company’s rapid growth and market penetration. “As we enter our next chapter of hyper-growth, I'm thrilled to have Simon joining our leadership team,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Simon will be instrumental in modernizing our global marketing engine and solidifying Armis as the definitive leader in cyber exposure management. He's a category creator
Americhem Appoints Kilian Lamprecht as Vice President of Mergers & Acquisitions to Accelerate Strategic Growth18.3.2026 12:00:00 CET | Press release
Americhem, a global leader in polymer solutions, today announced that Kilian Lamprecht has joined the company as Vice President of Mergers & Acquisitions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317304976/en/ Kilian Lamprecht, Vice President of Mergers & Acquisitions, Americhem Lamprecht brings extensive experience in corporate development and integration within global industrial and technology organizations. He will work closely with Americhem’s executive leadership team and investment partner PPC to identify and execute strategic acquisitions, partnerships and portfolio investments that expand the company’s capabilities, product portfolio and geographic reach. “Americhem has a long history of disciplined growth and innovation in materials science,” said John Richard, CEO of Americhem. “With the support of PPC, we are expanding our ability to pursue strategic acquisitions that strengthen our technology platform, b
Reply Announces a Partnership With Mistral AI to Develop Sovereign and Enterprise-grade Artificial Intelligence Solutions18.3.2026 09:00:00 CET | Press release
Reply [EXM, STAR: REY] today announced a new partnership agreementwithAI leader Mistral AI aimed at accelerating the adoption of local, customisable, secure and enterprise-grade generative AI solutions at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318232777/en/ Through this collaboration, Reply and Mistral AI provide a trusted and secure environment on European infrastructures, accelerating the adoption of advanced AI solutions while enabling organizations with stringent regulatory, privacy and data protection requirements to fully leverage generative AI. At the core of the collaboration is a shared vision of frontier AI, designed to enable organizations to adopt AI solutions while ensuring data control, protection of sensitive information, compliance with regulatory requirements and deployment on European infrastructures. By combining Mistral AI’s high-performance AI models with Reply’s expertise in designing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom